Sorafenib for the treatment of hepatocellular carcinoma across geographic regions
Journal
Expert review of Clinical Pharmacology
Journal Volume
2
Journal Issue
2
Pages
129-136
Date Issued
2009
Author(s)
Abstract
Sorafenib is an oral multikinase inhibitor targeting Raf, VEGF receptor, PDGF receptor, c-kit, Flt-3 and rearranged during transfection (RET), Two randomized, placebo-controlled trials for Western and Asian patients, respectively, demonstrated that sorafenib significantly prolongs overall survival and time to progression in patients with advanced hepatocellular carcinoma (HCC). These have become the reference treatment for future clinical trials of advanced HCC. Sorafenib is well tolerated in patients with Child - Pugh liver function class A, but limited data are available in Child - Pugh class B and C patients. Clinical trials are ongoing to test the efficacy of sorafenib-based combination therapy and sorafenib adjuvant therapy for HCC. ? 2009 Expert Reviews Ltd.
SDGs
Other Subjects
placebo; sorafenib; antineoplastic activity; area under the curve; article; cancer survival; clinical trial; desquamation; diarrhea; drug efficacy; drug half life; drug metabolism; drug stability; drug structure; drug tolerability; fatigue; geographic distribution; hand foot syndrome; human; kidney carcinoma; liver cell carcinoma; lung non small cell cancer; maximum plasma concentration; overall survival; rash; side effect; skin manifestation; survival time; tablet formulation
Type
journal article